A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, multicenter, open-label trial of avapritinib in patients aged 2 to less
than 18 years of age with with relapsed/refractory (R/R) solid tumors with mutations
(including non-synonymous point mutations, insertions, and deletions) in KIT or PDGFRA, or
gliomas with the H3K27M mutation, and no available alternative treatment options. This is a
single-arm trial in which all patients will receive avapritinib. The study consists of 2
parts: dose confirmation, safety, and PK (Part 1) and initial efficacy, safety, and PK at the
Part 2 recommended dose (Part 2).